Single Technologies

High-Level Overview

Single Technologies is a Stockholm-based deep tech company specializing in advanced DNA sequencing solutions through their proprietary 3-D Sequencing technology. Their platform integrates innovations in single molecule imaging, fluidics, optics, and nanotechnology to enable rapid, high-resolution sequencing with improved speed, capacity, and reagent efficiency. They primarily serve researchers, innovators, and companies in genomics and biotechnology, aiming to remove bottlenecks in sequencing data generation and empower scientists with AI-driven tools to solve complex biological problems. The company has demonstrated growth momentum by raising approximately $4.7 million from investors such as JovB Holding, Sciety, and KTH Holdings, and is preparing for a significant Series A funding round in early 2026 to support commercial rollout of a genomics data production facility[1][2][3][5].

Origin Story

Founded in 2012 by Johan Strömqvist (CEO), Bengt Sahlgren, Annika Bolind Bågenholm, and Raoul Stubbe, Single Technologies emerged from a unique blend of PhD research in single molecule imaging and biotechnology at the Royal Institute of Technology (KTH) and R&D expertise in fiber optical grating technology from the founders’ prior experience with Proximion. The idea originated from combining these scientific and engineering disciplines to push the limits of genomics by developing a new sequencing platform that leverages 3-D imaging and automated fluidics. Early traction included recognition by industry leaders in genomics and securing strategic funding, as well as advisory support from genomics pioneer Bob Kain, formerly of Illumina, which underscores their credibility and potential in the sequencing market[1][2][3].

Core Differentiators

• Innovative 3-D Sequencing Platform: Combines single molecule imaging, fast large-area confocal scanning, grating techniques, and nanotechnology to enable high-throughput, high-resolution sequencing.
• Automated Fluidics System (Theta): Avoids microchannels to allow rapid liquid exchange over large surfaces using fewer reagents, optimizing reaction efficiency.
• Compatibility with Fluorescent-Based Chemistry: Supports various sequencing chemistries with enhanced speed and capacity through patterned surface methods.
• Strong Scientific and Industry Network: Founded by experts with deep optical and biotech backgrounds, supported by notable advisors like Bob Kain.
• Focus on Speed, Capacity, and Cost Efficiency: Their technology aims to set new standards in sequencing throughput and reagent use, addressing key bottlenecks in genomics data generation[1][2][3][4].

Role in the Broader Tech Landscape

Single Technologies is positioned at the intersection of genomics, biotechnology, and AI-driven data analysis, riding the wave of increasing demand for large-scale, high-quality sequencing data. The timing is critical as the genomics field faces bottlenecks in data generation speed and cost, which their 3-D Sequencing technology directly addresses. Market forces such as the growth of personalized medicine, drug discovery, and biological research amplify the need for scalable sequencing platforms. By enabling faster and more efficient sequencing, Single Technologies influences the broader ecosystem by accelerating innovation, facilitating new biological insights, and potentially disrupting established sequencing technologies dominated by companies like Illumina[1][2][3][4].

Quick Take & Future Outlook

Looking ahead, Single Technologies is preparing for a substantial Series A funding round in early 2026, which will support the commercial rollout of their genomics data production facility. This expansion is expected to accelerate adoption of their 3-D Sequencing platform and broaden their impact in genomics research and diagnostics. Future trends shaping their journey include continued integration of AI for data analysis, increasing demand for multi-dimensional sequencing data, and the push towards more cost-effective, high-throughput sequencing solutions. Their influence is likely to grow as they enable new applications in omics and personalized medicine, potentially reshaping the sequencing landscape by offering a novel, scalable alternative to existing technologies[2][3][5].

In summary, Single Technologies stands out by combining cutting-edge optical and fluidic innovations to overcome current sequencing limitations, empowering scientists to unlock new dimensions in genomics research.